SCHEMBL3707249

SCHEMBL3707249

COCNC(=O)c1ccc2ncnc(Cl)c2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.43
MMP13 P45452 2/20 0.42
ALDH1A1 P00352 4/20 0.41
CYP3A4 P08684 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CDK1 P06493 1/20 0.41
ENPP1 P22413 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
MTNR1A P48039 3/20 0.39
MTNR1B P49286 3/20 0.39
CNR1 P21554 1/20 0.39
WDR91 A4D1P6 1/20 0.38
EGFR P00533 1/20 0.38
ERBB2 P04626 1/20 0.38
KDR P35968 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3705273 0.86 MTNR1A (0.42) HPGDMMP13ALDH1A1CYP3A4TSHR
SCHEMBL496982 0.81 CSNK2A1 (0.51) HPGDALDH1A1ENPP1CNR1KDM4E
SCHEMBL29894777 0.81 CSNK2A1 (0.51) HPGDALDH1A1ENPP1CNR1KDM4E
SCHEMBL28806345 0.76 SLC2A1 (0.53) ALDH1A1CYP3A4ENPP1NPC1RAB9A
SCHEMBL1644905 0.75 MEN1 (0.61) HPGDALDH1A1HSD17B10NPC1RAB9A
SCHEMBL1680503 0.75 ALDH1A1 (0.56) HPGDALDH1A1TSHRHSD17B10NPC1
SCHEMBL14782829 0.74 HPGD (0.43) HPGDALDH1A1NPC1RAB9AMEN1
SCHEMBL5191348 0.74 PDE4A (0.47) HPGDALDH1A1TSHRHSD17B10NPC1
SCHEMBL3705150 0.74 EGFR (0.47) EGFRERBB2KDR
SCHEMBL6957121 0.74 CYP3A4 (0.42) HPGDALDH1A1CYP3A4TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1854789-B1 QUINAZOLINE DERIVATIVE HAVING TYROSINE KINASE INHIBITORY ACTIVITY SHIONOGI & CO (JP) 2013-10-09 EP disclosed
US-8349857-B2 Quinazoline derivatives having tyrosine kinase inhibitory activity SHIONOGI & CO., LTD. (JP) 2013-01-08 US disclosed
US-8202879-B2 Quinazoline derivatives having tyrosine kinase inhibitory activity SHIONOGI & CO., LTD. (JP) 2012-06-19 US disclosed
US-20120123114-A1 QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2012-05-17 US disclosed
US-20090143414-A1 Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity SHIONOGI & CO., LTD. (JP) 2009-06-04 US disclosed
EP-1854789-A1 QUINAZOLINE DERIVATIVE HAVING TYROSINE KINASE INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2007-11-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143414-A1 Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity ERBB2, EGFR, ABL1 HPGD 3062/4885MMP13 2562/4885ALDH1A1 4593/4885
US-20120123114-A1 QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY ERBB2, EGFR, ABL1 HPGD 3062/4885MMP13 2562/4885ALDH1A1 4593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.